MCL Literature Feed

A novel fluorescence-based assay quantifies pirtobrutinib in biological fluids, potentially enabling therapeutic drug monitoring to optimize dosing, manage toxicity, and study resistance in MCL patients.

This meta-analysis quantifies the high incidence of neurotoxicity (ICANS) with brexucabtagene autoleucel in MCL, finding 61% of patients experience any grade and 33% experience severe events.

This case report describes the rare co-occurrence of MCL and CLL/SLL, highlighting the diagnostic and therapeutic challenges that require careful pathologic evaluation to guide appropriate treatment.

This Chinese real-world study confirms autologous transplant consolidation improves survival in young, fit, lower-risk MCL, with added benefit from post-transplant maintenance using novel agents.

Flow cytometry is crucial for accurately diagnosing leukemic-phase blastoid MCL, resolving morphological ambiguity with other acute leukemias and ensuring correct treatment for this aggressive variant.

This bioinformatic study identified a prognostic network of six circular RNAs in mantle cell lymphoma that regulate key pathways like BCR signaling, suggesting their potential as novel biomarkers.

Real-world data from an Italian compassionate use program confirms pirtobrutinib's efficacy in heavily pre-treated, relapsed/refractory MCL, including patients who have failed prior covalent BTK inhibitors.

This review outlines the historical evolution in understanding transformed mantle cell lymphoma, highlighting changes in its pathological diagnosis, genomic drivers, and the clinical challenges it presents.

This preclinical development of an optimized CXCR4-targeting theranostic pair offers a novel strategy to simultaneously image and treat MCL by targeting a key pathway in aggressive disease.

This case report details a rare, life-threatening presentation of MCL with massive pleural effusions requiring mechanical ventilation, highlighting a severe form of serosal involvement and its management.

Co-expression of PD-L1/PD-1 with CXCR3 and systemic inflammation indices (SIRI, SII) identified advanced stage and poor survival in a mixed lymphoma cohort, offering potential prognostic biomarkers for MCL.

This review summarizes cutaneous toxicities across different BTK inhibitors, highlighting the improved skin safety profile of newer agents, which is critical for managing long-term MCL therapy.

This study demonstrates that TP53 mutation heterogeneity, not just presence, defines distinct prognostic subgroups in MCL, enabling more precise risk stratification beyond a simple binary classification.

Long-read sequencing systematically identifies novel fusion transcripts in MCL, potentially revealing new prognostic biomarkers and therapeutic targets beyond the canonical t(11;14) translocation.

In a real-world French cohort, MCL patients failing CAR-T therapy have dismal outcomes (median OS 5.8 months), highlighting an urgent need for effective salvage, with bispecific antibodies showing promise.

This review outlines the evolution of BTK inhibitors, highlighting how non-covalent agents like pirtobrutinib overcome C481-mediated resistance, extending the therapeutic sequence for relapsed/refractory MCL.

This case report details a rare MCL-induced paraneoplastic 'full-house' nephropathy mimicking lupus nephritis, which resolved with lymphoma-directed therapy, expanding the spectrum of known renal complications.

This general review of lymphoproliferative disorders reiterates the established role of bortezomib in relapsed/refractory mantle cell lymphoma but provides no new data or specific insights.

This review highlights the improved cardiovascular safety of next-generation BTK inhibitors over ibrutinib, which is critical for MCL treatment selection and long-term management of associated cardiac toxicities.

Mendelian randomization provides genetic evidence that obesity is a causal risk factor for developing mantle cell lymphoma, identifying a potentially modifiable risk factor for the disease.

This preclinical mouse study shows zanubrutinib mitigates pulmonary fibrosis by inhibiting the Wnt/β-catenin pathway, a novel off-target mechanism potentially relevant to managing toxicities in MCL patients.

In the phase 3 TRIANGLE trial for young, fit MCL, adding ibrutinib to induction immunochemotherapy improves failure-free survival, with noninvasive genotyping confirming its efficacy and treatment dynamics.

A new genomic model integrating mutations (e.g., TP53) and copy number variations improves risk stratification for elderly, newly diagnosed MCL patients treated with chemoimmunotherapy.